Get the Stockscreener App
5.03
2.14%
-0.11
After Hours:
5.03
Sight Sciences Inc stock is traded at $5.03, with a volume of 150.61K.
It is down -2.14% in the last 24 hours and up +17.80% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
See More
Previous Close:
$5.14
Open:
$5.19
24h Volume:
150.61K
Relative Volume:
0.45
Market Cap:
$273.68M
Revenue:
$77.36M
Net Income/Loss:
$-38.43M
P/E Ratio:
-6.79
EPS:
-0.7408
Net Cash Flow:
$-29.92M
1W Performance:
+1.00%
1M Performance:
+17.80%
6M Performance:
-30.72%
1Y Performance:
+53.35%
1-Day Range:
$4.97
$5.23
1-Week Range:
$4.66
$5.23
52-Week Range:
$3.11
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
5.03 | 279.67M | 77.36M | -38.43M | -29.92M | -0.7408 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-08-25 | Upgrade | Lake Street | Hold → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight Sciences wins $34M patent ruling against Alcon - MSN
Sight Sciences Inc. (SGHT) Q1 2026 Earnings: EPS Misses Estimates as Operating Losses WidenEarnings Growth Analysis - Newser
Sight Sciences Inc. (SGHT) Q1 2026 Earnings: Wider-Than-Expected Loss Drags Stock Down Over 2%Tax Rate Impact - Newser
Sight Sciences stock (US8177721062): eye-care specialist in focus after latest business update - AD HOC NEWS
Sight Sciences (SGHT) Q1 2026 Results Disappoint — Multiple Headwinds CitedSocial Buzz Stocks - Newser
Sight Sciences (SGHT) Fell -0.64% — Is a Recovery Ahead? 2026-05-20Sector Neutral Pair - Newser
Sight Sciences (SGHT) COO sells 12,728 shares to cover RSU tax obligations - Stock Titan
Sight Sciences stock (US8177721062): eye-care specialist in focus after recent earnings and FDA upda - AD HOC NEWS
Sight Sciences appoints Ali Bauerlein as COO and Jim Rodberg as CFO - MSN
Sight Sciences signals $83M-$89M 2026 revenue outlook while targeting $6M-$8M dry eye sales - MSN
sight sciences, inc. Earnings dates - RTTNews
Affiliate plans sale of 12,728 SGHT shares (NASDAQ: SGHT) via Fidelity - Stock Titan
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
TradingKey - tradingkey.com
Sight Sciences (SGHT) Climbs +2.86% — Resistance at $5.29 in Focus 2026-05-14Investment Community - Newser
SGHT (Sight Sciences) posts wider-than-expected loss as earnings miss forecasts by 42%, shares dip.Wall Street Picks - Newser
Sight Sciences (SGHT) Q1 Loss Of US$0.24 EPS Tests Margin Improvement Narrative - Sahm
SGHT (Sight Sciences) beats Q1 earnings estimates by 5.1% as shares climb 1.70% on optimism.Trader Community Insights - newser.com
Insiders At Sight Sciences Sold US$1.8m In Stock, Alluding To Potential Weakness - Moomoo
Sight Sciences(SGHT) Stock Options Chain | Quotes & News - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Sight Sciences Financial Results for Q1 2026 Show Growth - VisionMonday.com
Sight Sciences Earnings Call Signals Disciplined Growth - TipRanks
Lake Street Initiates Sight Sciences(SGHT.US) With Buy Rating, Announces Target Price $12 - Moomoo
Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2026 Earnings Call Transcript - Insider Monkey
Needham Maintains Sight Sciences(SGHT.US) With Hold Rating - Moomoo
Piper Sandler Maintains Sight Sciences(SGHT.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Sight Sciences (SGHT) Q1 2026 Earnings Transcript - AOL.com
Sight Sciences Q1 Earnings Call Highlights - Yahoo Finance
Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - sharewise.com
Sight Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Sight Sciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
SGHT: Double-digit revenue growth and raised guidance, with strong segment execution and patent win - TradingView
Earnings call transcript: Sight Sciences Q1 2026 revenue up, EPS misses By Investing.com - Investing.com South Africa
Earnings call transcript: Sight Sciences Q1 2026 revenue up, EPS misses - Investing.com
Sight Sciences Lifts 2026 Outlook After Strong Q1 - TipRanks
Sight Sciences (NASDAQ: SGHT) grows Q1 2026 sales and wins $55.4M judgment - Stock Titan
Sight Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Sight Sciences (NASDAQ: SGHT) boosts 2026 revenue outlook after strong Q1 - Stock Titan
BRIEF-Sight Sciences Q1 Revenue USD 19.7 Million Vs. IBES Estimate USD 18.5 Million - TradingView
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance - ChartMill
Sight Sciences Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Sight Sciences Publishes Its 2025 Sustainability Report - VisionMonday.com
Sight Sciences to Present at Two Upcoming Investor Conferences - The Manila Times
Sight Sciences (SGHT) to Release Earnings on Wednesday - MarketBeat
Sight Sciences maps out two May investor conference appearances - Stock Titan
Sight Sciences Issues 2025 Sustainability Report on ESG Initiatives - VisionMonday.com
Sight Sciences awarded $55.4 million in patent case against Alcon By Investing.com - Investing.com Canada
Sight Sciences awarded $55.4 million in patent case against Alcon - Investing.com
Sight Sciences Wins Patent Judgment, Secures Ongoing Royalties - TipRanks
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):